InvestorsHub Logo
Followers 840
Posts 120463
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 117

Tuesday, 02/25/2020 12:07:11 PM

Tuesday, February 25, 2020 12:07:11 PM

Post# of 254
EOLS 4Q19 Jeuveau/Nuceiva* sales=$19.5M, up from $13.5M in 3Q19:

https://investors.evolus.com/news-releases/news-release-details/evolus-reports-fourth-quarter-and-full-year-2019-results-and

The $19.5M sales in 4Q19 consisted of $18.8M in the US and $0.7M in Canada, where EOLS has delegated sales and marketing to Clarion Medical (http://www.koreaherald.com/view.php?ud=20191017000697 ).

EOLS had not yet had any sales in the EU and doesn’t expect any sales there until 2H20 at the earliest.

4Q19 net loss=$14.5M; 12/31/19 cash=$129.8M.

Lamely, EOLS is offering no financial guidance whatsoever for 2020.

As I’m typing, EOLS is down 24% from its $12.00 IPO price two years ago (https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138370054 ).

*Nuceiva is the brand name for Jeuveau in the EU and Canada.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EOLS News